3Elrishi MA, Khunti K,Jarvis J,et al.The dipeptidyl-peptidase-4(DDP-4) inhibitors:A new class of oral therapy for patients with type 2 diabetes mellitus[J].Prac Diabetes Int,2007,24(9):474.
4Nfchan V,Yang W,Son HY,et al.Efficacy and safety of sitaglitin in the treatment of patients with 2 diabetes in China,India,and Korea [J].Diabetes Res Clin Pract,2009,83(1):106.
6IDF Clinical Guidelines Task Force, Global guideline for Type 2 Diebetes; recommendations for standard, comprehensive, and minimalcare[J]. Diebet Med, 2006,23 : 579-593.
7Nathna DM, Buse JB, Davidson MB,et al. Management of hyperglycaemia in type 2 diebetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diebetes Association and the Europen Association for the Study of Diebetes[J].Diabetologia, 2006,49 : 1711-1721.
8Rat ner R,Gotdberg R, Haffner S, et al. Impact of intensive lifestyle and meformin therapy O15 cardiovascular disease risk factors in the diabetes prevention program [J].Diebetes Care, 2005,28: 888-894.
9Venugppalan P, Sapare A, Venkatesan N, et al. Pelleted dioadhesive polymeric nan oparticles for buccal delivery of insulin: preparation and characterization [J].Pharmazie, 2001,56 ( 3 ) : 217-219.
10Leon DD, Crutchlow MF,Ham JY ,et al. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus [ J ]. Int J Biochem Cell Biol, 2006,38 (5-6) :845.
